about
Critically ill patients with cancer: chances and limitations of intensive care medicine-a narrative reviewExpert statements on the standard of care in critically ill adult patients with atypical haemolytic uraemic syndrome.Immune-mediated disorders causing bleeding or thrombosis in lymphoproliferative diseases.Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complicationsPostoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours.Acquired hemophilia A: Updated review of evidence and treatment guidance.Summary report of the First International Conference on inhibitors in haemophilia A.Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML.Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry.Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry.Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.Myocardial involvement in a patient with Burkitt's lymphoma mimicking hypertrophic cardiomyopathy.Is It HIT?Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b dataThrombotic thrombocytopenic purpuraInitial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpuraPrevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia AEnhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitusIs there an association between hemostatic abnormalities and the outcome of acute lung injury?Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trialExpert statement on the ICU management of patients with thrombotic thrombocytopenic purpuraA randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A
P50
Q28072563-4DA52409-06C2-4C7B-A2E4-4B259B3C7AEBQ30234666-30230EF0-D22F-4F68-9942-E02A3BA30849Q33413831-A351BB08-2DC2-4854-97D9-BF6507F62637Q34155511-905E8F79-C6D6-41C1-A9F0-53DAADD22881Q36079810-54B618E6-277B-40E0-99E6-D7A889D7F5C0Q37290652-689BD96E-F3A1-4CED-BDEA-11FCB0CA2FE8Q37860399-927C86A4-3BDF-458A-AC59-8E0415BC39ABQ38805567-FE305CA5-C9FC-4616-B03B-052E79CDAB63Q39022123-64E39F90-1A56-4506-8CFD-6BE5223ED3F7Q40138696-1808E88E-953F-4572-AD3D-EF653D4643C8Q40575708-C1050F89-F5FB-435C-87E2-F49866A5914EQ43247819-23704A5E-28D9-452A-BB50-833CA6A9E49FQ43776393-173EE1FB-ACB1-4CC5-AB64-8240D363A6CDQ45872638-F86AB282-C7CC-4F8B-8C46-7A8C78C88A91Q45879231-D45FE189-A5CE-4633-B082-04CD52DE2147Q45879327-9F923426-D008-4692-98A7-1BB087F40563Q53637058-4A739BA4-7EB1-4989-936B-99CD25BC5671Q53714550-93CCAC8C-B450-4ED8-A988-D3A7ED36223BQ58580520-A661004F-AA00-4D01-8F34-B230894BF081Q58767790-85CD3D16-7CD6-400E-9EBB-0532EC24EA90Q59567016-46BAA8EE-4DA0-471F-B0B6-AD6033D84818Q60302918-C4CB9A04-13DB-4944-B77E-DC1137F272D8Q72198405-2F44163D-4AAE-43B9-B5E9-F3FBBA34482DQ80712827-CBB3657A-8F98-4774-82F8-27345AA88593Q84938109-16B6BCEF-F49D-43EB-8FDF-33972965FC14Q90549947-7FAA8661-8050-408F-BF9B-DA54D936DEE3Q91102547-4F440282-FF7B-469B-B612-572291ADF0CB
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-7909-7225
@en
name
P Knoebl
@ast
P Knoebl
@en
P Knoebl
@nl
type
label
P Knoebl
@ast
P Knoebl
@en
P Knoebl
@nl
prefLabel
P Knoebl
@ast
P Knoebl
@en
P Knoebl
@nl
P214
P244
P106
P214
P244
nb2008027535
P31
P496
0000-0002-7909-7225
P7859
lccn-nb2008027535